Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
The Ma’anshan site approval covers pastilles, oral liquids, and powders
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The facility has been designed with a dual focus on efficiency and sustainability
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Subscribe To Our Newsletter & Stay Updated